Xencor reported $58.18M in Operating Expenses for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Expenses Change
Abbvie ABBV:US $ 11288M 2467M
Alnylam Pharmaceuticals ALNY:US $ 416.5M 56.51M
Amgen AMGN:US $ 4.42B 680M
Arrowhead Research ARWR:US $ 105.32M 4.93M
AstraZeneca AZN:LN 10.23B 280M
Biogen BIIB:US $ 2648.2M 727.1M
Bristol Myers Squibb BMY:US $ 9.3B 202M
Cytokinetics CYTK:US $ 99.84M 18.14M
Epizyme EPZM:US $ 59.62M 3.25M
GlaxoSmithKline GSK:LN 5.85B 1.13B
Johnson & Johnson JNJ:US $ 18.18B 616M
Karyopharm Therapeutics KPTI:US $ 82.59M 331K
Macrogenics MGNX:US $ 77.74M 5.36M
Merk MRK:US $ 9666M 666M
Novartis NOVN:VX 10.86B 895M
Pfizer PFE:US $ 15640M 148M
Regeneron Pharmaceuticals REGN:US $ 1747.3M 40.7M
Seattle Genetics SGEN:US $ 630.61M 71.1M
Xencor XNCR:US $ 58.18M 854K